Nesiritide and Renal Function After the Total Artificial Heart

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Congestive Heart Failure, Cardiorenal Syndrome

In brief

The prevalence of renal dysfunction after implantation of the artificial heart is high. The infusion of exogenous B-type natriuretic peptide (BNP) after implantation of the total artificial heart (TAH) improves renal function in a sustained manner. The renal protective and hormone-modulating effects of nesiritide may be enhanced with ventriculectomy compared to heart failure surgery that leaves the native myocardium intact. The goal of this project is to determine the renal protective effects of nesiritide after implantation of a mechanical device.

Key facts

Study ID

NCT01836809

Run by

Virginia Commonwealth University

People needed

2

Starts

2013-04-01

Expected to finish

2014-05-01

Last updated by the study team

2016-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Implanted with a total artificial heart (CardioWest) or Left ventricular assist device (HeartMate II)
• Age > 18 years

You may not qualify if…

• Previous calcineurin inhibitor (CNI) exposure
• Hemodialysis prior to device implant

Where it is running

• Virginia Commonwealth University Medical Center — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.